Toceranib-d8 (SU11654-d8) 是 Toceranib 的氘代物。Toceranib (SU11654) 是一种口服活性受体酪氨酸激酶 (RTK) 抑制剂，能有效抑制PDGFR，VEGFR，Kit，抑制 PDGFRβ 和 Flk-1/KDR 的 Ki 值分别为 5 nM 和 6 nM。Toceranib 具有抗肿瘤和抗血管生成活性，用于犬肥大细胞肿瘤的研究。
| 生物活性 |
Toceranib-d8 (SU11654-d8) is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors. |
|---|---|
| 体外研究 |
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. |
| 分子量 |
404.51
|
| CAS号 |
1795134-78-9
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
纯度： 98%
关注我们
获得KKL MED 最新资讯
咨询热线：
400-881-9290
Data Sheet